| Etelcalcetide | Amgen | ||
| 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL; Solution, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. | |||
|
Yes
| |||
| Parsabiv | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
|---|---|---|---|---|---|---|---|
| ********* | ******* ***** ******** ************ | ******* ***** ******** ************ | **** *** | **** *** | **** *** | **** *** | ******* ***** ******** ************ |
| *** **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** |
| *** ******* ******* | **** ** ***** **, **** | **** ** ***** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | **** ** ***** **, **** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ********* | *** \ *** | *** **, **** | ******* | ********* ******** | ******* *** **, **** (******** ******) *** *** **** |
| *** **** | ***\ ********* | *** **, **** | ******* | ********* ******** | *** ****** *** **, **** (******** ******) |
| *** ******* ******* | **\ ** | *** **, **** | ******* | **** | *** ****** *** **, **** (******** ******) |
Download ParaIV Report